Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Equity: 2021-2025

Historic Return on Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 0.07%.

  • Kiniksa Pharmaceuticals International's Return on Equity rose 26.00% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 26.00%. This contributed to the annual value of -0.10% for FY2024, which is 5.00% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Return on Equity stood at 0.07%, which was up 593.17% from 0.01% recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Return on Equity's 5-year high stood at 0.79% during Q2 2023, with a 5-year trough of -0.83% in Q4 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Return on Equity averaged around 0.09%, with its median value being -0.04% (2025).
  • In the last 5 years, Kiniksa Pharmaceuticals International's Return on Equity surged by 154bps in 2023 and then plummeted by 98bps in 2024.
  • Kiniksa Pharmaceuticals International's Return on Equity (Quarterly) stood at -0.83% in 2021, then skyrocketed by 152bps to 0.69% in 2022, then plummeted by 83bps to -0.14% in 2023, then increased by 4bps to -0.10% in 2024, then grew by 26bps to 0.07% in 2025.
  • Its last three reported values are 0.07% in Q3 2025, 0.01% for Q2 2025, and -0.04% during Q1 2025.